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ABSTRACT
BACKGROUND: Less than two-thirds of

children with abdominal pain in the
emergency department receive analgesia. We sought to determine whether
hyoscine butylbromide was superior to
acetaminophen for children with nonspecific colicky abdominal pain.

METHODS: We randomly allocated chil-

dren aged 8–17 years with nonspecific
colicky abdominal pain who presented to
the pediatric emergency department of
London Health Sciences Centre, London,
Ontario to receive hyoscine butylbromide, 10 mg given orally, or acetaminophen, 15 mg/kg given orally (maximum
975 mg). We considered the minimal clinically important difference for the primary outcome (self-reported pain at
80 min) to be 13 mm on a 100 mm visual

A

analogue scale. Secondary outcomes
included administration of rescue analgesia, adverse effects and pain score less
than 30 mm at 80 minutes.
RESULTS: A total of 236 participants
(120 in the hyoscine butylbromide
group and 116 in the acetaminophen
group) were included in the trial. The
mean visual analogue scale scores
at 80 minutes were 29 mm (standard
deviation [SD] 26 mm) and 30 mm
(SD 29 mm) with hyoscine butylbromide and acetaminophen, respectively
(adjusted difference 1, 95% confidence
interval –7 to 7). Rescue analgesia was
administered to 4 participants (3.3%)
in the hyoscine butylbromide group
and 1 participant (0.9%) in the aceta
minophen groups (p = 0.2). We found

bdominal pain is reported by a third of school-aged children1 and accounts for several visits daily in most emergency departments.2–5 Although the use of analgesia to
treat acute abdominal pain is well-supported,6,7 there is little evidence to guide the management of nonspecific abdominal pain in
the emergency department,8 which accounts for two-thirds of cases
of abdominal pain presenting to the emergency department.8,9
Acetaminophen is the most commonly used World Health Organ
ization Step 1 analgesic.10 In children, it is effective for many painful
conditions,11,12 but data supporting its use for abdominal pain are
lacking.13,14 Despite strong advocacy by the American Academy of
Pediatrics15 for adequate pain management, less than two-thirds of
children with abdominal pain in the emergency department receive
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no significant differences in rates of
adverse effects between hyoscine
butylbromide (32/116 [27.6%]) and
acetaminophen (28/115 [24.3]) (p =
0.5); no serious adverse effects were
observed. The proportion with a pain
score less than 30 mm at 80 minutes
was 66 (55.0%) with hyoscine butylbromide and 63 (54.3%) with acetaminophen (p = 0.9).
INTERPRETATION: Hyoscine butylbro-

mide was not superior to acetaminophen in this setting. Both agents were
associated with clinically important pain
reduction, and either can be considered
for children presenting to the emergency department with nonspecific colicky abdominal pain. Trial registration:
Clinicaltrials.gov, no. NCT02582307

analgesia,16,17 and roughly half experience ongoing pain after discharge.18 Children with nonspecific abdominal pain are less likely
than those with a specific cause to receive analgesia.5 Available
analgesic options for children with nonspecific abdominal pain in
the emergency department may result in greater adherence to the
American Academy of Pediatrics recommendations.
Hyoscine butylbromide is orally administered and available in
most Canadian emergency departments. We surmised that it may
be effective for colicky abdominal pain owing to its antispasmodic
properties.19 Ten placebo-controlled studies involving 3699 adults
with functional abdominal pain showed hyoscine butylbromide to
be beneficial, without serious adverse effects.20–29 In the only pediatric study, hyoscine butylbromide, 10 mg given orally, was found
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Methods
Study design and setting
We conducted a double-blind randomized trial to test the hypothesis
that hyoscine butylbromide is superior to acetaminophen for children with nonspecific colicky abdominal pain. Research assistants
(K.K., S.B., S.E., E.D.) screened consecutive potentially eligible participants in the pediatric emergency department of London Health Sciences Centre, London, Ontario, daily between the hours of 1700 and
2400 from Mar. 20, 2017, to Dec. 3, 2018. The emergency department
has an annual census of 38 000 visits and is the only pediatric surgical
referral centre in southwestern Ontario.

Participant selection
We included children aged 8–17 years with abdominal pain selfreported as “crampy,” “coming in waves” or “squeezing,” and
rated as 40 mm on a 100 mm visual analogue scale31 at its least
intense. Pain was assessed immediately before enrolment. Children were excluded if they were unable to swallow pills or com
municate verbally, currently used an anticholinergic, had hypersensitivity to acetaminophen, hyoscine butylbromide or
applesauce vehicle, had received acetaminophen or hyoscine
butylbromide within 6 hours of enrolment, had incurred abdom
inal trauma within 48 hours of enrolment or had medical record
evidence of abdominal or genitourinary disease; those in whom a
surgical or medical cause for the pain (e.g., appendicitis, renal
colic, bowel obstruction) was suspected clinically or radiographic
ally were also excluded. The full study protocol is provided in
Appendix 1 (available at www.cmaj.ca/lookup/doi/10.1503/
cmaj.201055/tab-related-content).We used a 5-member focus
group of caregivers of children with abdominal pain to inform the
terminology for describing colicky abdominal pain, lower age limit
for swallowing pills, and consent and assent forms.
Participants were randomly allocated in a 1:1 allocation ratio with
permuted block sizes to either single-dose hyoscine butylbromide in
tablet form, 10 mg given orally (Boehringer Ingelheim),30 plus placebo
acetaminophen liquid (Perrigo); or acetaminophen liquid, 15 mg/kg
given orally to a maximum of 975 mg (McNeil Consumer Healthcare)
plus placebo hyoscine butylbromide tablet (Perrigo). Preparation of
medications, allocation concealment and implementation of randomization were pharmacy controlled. The randomization list was
generated with a computer-based random-number generator (www.
randomization.com). Allocation concealment was performed by
means of sequentially numbered, opaque, sealed envelopes.
Medications were administered by the bedside nurse. If the
patient vomited within 30 minutes of receiving the medication,
another dose was given. Rescue analgesia was permitted at any
time. Blinded parties included the participant, caregiver, emergency department personnel and all members of the study team
apart from the pharmacist.

Outcomes
Outcome data were collected by research assistants (K.K., S.B., S.E.,
E.D.) using an iPad hosting the Research Electronic Data Capture
(REDCap) platform.32 The primary outcome was self-reported pain
80 minutes after the intervention, assessed with a 100 mm visual analogue scale.33 Eighty minutes reflects the time to peak analgesic action
of hyoscine butylbromide19 and acetaminophen (60–90 min).34,35 The
visual analogue scale has been used in trials of analgesics in children
older than 6 years of age36,37 and there are abundant data establishing
its reliability.38–43 Secondary outcomes included rescue analgesia,
adverse effects and a visual analogue scale pain score less than
30 mm after the intervention, the World Health Organization target for
effective analgesia.44 The following adverse effects were considered
serious: hospital admission due to a drug-related event, prolongation
of existing hospital stay, persistent or major disability or incapacity, a
life-threatening outcome and death. Other secondary outcomes
included caregiver satisfaction with pain management, assessed with
a Likert scale ranging from 1 (very unsatisfied) to 5 (very satisfied), selfreported pain scores 15, 30, 45 and 60 minutes after the intervention,
return visits to a health care provider, missed surgical diagnoses
within 72 hours of emergency department discharge, emergency
department length of stay, discharge diagnosis, disposition and time
to a 20% reduction in preintervention pain (Appendix 2, available at
www.cmaj.ca/lookup/doi/10.1503/cmaj.201055/tab-related-content).
All outcomes were prespecified except pain after discharge, length of
emergency department stay and missed surgical diagnoses (data collected by means of a telephone survey with caregivers at 72 h, as
detailed in Appendix 2).

Deviations from registered protocol
Deviations from the registered protocol are detailed in Appendix 1.
The most significant deviation was that only the visual analogue
scale was used to determine eligibility and assess pain because it
has established reliability when used with a tablet device38 and we
believed it to be more acceptable to the age of the participants.

Sample size
We used a minimal clinically important difference on the visual
analogue scale of 13 mm between groups based on a derivation
cohort45 and a validation cohort,39 and an adult emergency department study of hyoscine butylbromide and acetaminophen for
abdominal pain.46 With a standard deviation (SD) of 30 mm,
112 children per group were required to detect a difference at the
5% 2-sided level of significance with 90% power. The sample size
was increased to account for dropouts, giving a final sample size of
115 participants per group.

Statistical analysis
Analyses of efficacy outcomes were based on intention to treat. In
participants without an 80-minute visual analogue scale score, we
assumed that the score was unchanged from the preintervention
pain score. Analysis of adverse effects and of caregiver satisfaction
was based on a per protocol analysis. We performed inferential statistics on primary and secondary efficacy outcomes. We used means
and SDs, frequencies and percentages, and medians and interquartile ranges (IQRs) to summarize ratio, categoric and o
 rdinal data,
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to be beneficial compared to a homeopathic preparation in
204 children, with no serious adverse effects.30 We sought to determine whether hyoscine butylbromide was superior to acetaminophen in relieving pain among children presenting to the emergency department with nonspecific colicky abdominal pain.
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respectively. We compared pain scores at 80 minutes between
groups using linear regression, adjusting for pain score immediately
before the intervention. We reported time to achieve at least a 20%
reduction in preintervention pain using a Kaplan–Meier survival
analysis. We compared categoric variables using the Pearson χ2 test
and adverse events using the Fisher exact test. Post hoc regression
analyses explored the effect of analgesia provided more than
6 hours before the intervention on the primary outcome with a test

of interaction. We analyzed the data using SPSS version 24 (IBM
Corp.). We considered p values less than 0.05 statistically significant.

Ethics approval
The protocol received approval from Western University’s Health
Sciences Research Ethics Board. The committee would not
approve the use of a placebo. The trial was monitored by an independent data safety monitoring board.

Patients screened for
eligibility
n = 4818
Excluded n = 4370

• Did not meet inclusion criteria n = 2763
• Met exclusion criteria n = 1607

o History of abdominal disorder* n = 290
o Received acetaminophen or HBB within 6 h n = 260
o Suspected urinary tract infection (n = 201),
constipation (n = 151), gynecologic disorder (n = 70),
gastroesophageal reflux (n = 48), biliary disorder
(n = 20), testicular disorder (n = 25), foreign body
ingestion (n = 10), hemodynamic compromise (n = 7),
renal colic (n = 8), mesenteric adenitis (n = 7),
pancreatitis (n = 6), vaso-occlusive crisis (n = 1),
abdominal neoplasm (n = 1), Henoch–Schönlein
purpura (n = 1)
o Underlying medical condition† n = 150
o Hospital admission n = 99
o Unable to communicate in English n = 85
o Gross lower gastrointestinal bleeding n = 42
o Unable to swallow pills n = 38
o Pregnant n = 28
o Previous enrolment in trial n = 25
o Current use of anticholinergic n = 16
o Persistent vomiting despite antiemetic n = 10
o Acetaminophen or HBB hypersensitivity n = 6
o Signs of peritoneal inflammation n = 2

Eligible participants
n = 448
Declined consent n = 212
Randomized
n = 236

Received acetaminophen
n = 116

Received HBB
n = 120
Lost to follow-up n = 36

Lost to follow-up n = 32

• Did not complete 80-min
pain score n = 4
• Did not complete 72-h
survey n = 32

• Did not complete 80-min
pain score n = 1
• Did not complete 72-h
survey n = 31

Completed all study
outcomes
n = 84

Completed all study
outcomes
n = 84

Figure 1: Flow diagram showing participant selection. *History of abdominal disorder included abdominal surgery (n = 167), abdominal trauma within
48 hours (n = 42), cyclic vomiting (n = 24), celiac disease (n = 18), hepatobiliary disease (n = 14), bowel obstruction (n = 13) and chromosomal abnormality
affecting abdominal viscera (n = 12). †Underlying medical conditions included congenital renal anomaly (n = 55), congenital genitourinary anomaly (n = 53),
inflammatory bowel disease (n = 37), pelvic inflammatory disease (n = 3), neutropenia (n = 1) and tuberculosis (n = 1). Note: HBB = hyoscine butylbromide.
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Table 1 (part 2 of 2): Baseline characteristics of children
with nonspecific colicky abdominal pain randomized to
receive hyosine butylbromide or acetaminophen

No. (%) of patients*

Characteristic
Female sex

Hyoscine
butylbromide
n = 120

Acetaminophen
n = 116

79 (65.8)

74 (63.8)

No. (%) of patients*
Hyoscine
butylbromide
n = 120

Acetaminophen
n = 116

Orthopedic

4 (3.3)

1 (0.9)

Characteristic

Age, mean ± SD, yr

12.5 ± 3.1

12.4 ± 2.9

In-toeing

2 (1.7)

1 (0.9)

Duration of pain before
enrolment, median (IQR), h

2 (0.5 to 5)

1.8 (0.5 to 4.8)

Scoliosis

1 (0.8)

0 (0.0)

Osteochondritis dessecans

1 (0.8)

0 (0.0)

4 (3.3)

2 (1.7)

Turner syndrome

1 (0.8)

1 (0.9)

Short stature

1 (0.8)

1 (0.9)

Menorrhagia

1 (0.8)

0 (0.0)

Type I diabetes mellitus

Received analgesia before
enrolment†

Endocrinologic

Acetaminophen

13 (10.8)

9 (7.8)

Ibuprofen

20 (16.7)

24 (20.7)

Ketorolac

2 (1.7)

4 (3.4)

Received antiemetic in
emergency department before
enrolment‡

28 (23.3)

23 (19.8)

Received antacid in emergency
department before enrolment§

2 (1.7)

2 (1.7)

Comorbidities¶

1 (0.8)

0 (0.0)

Ophthalmologic

0 (0.0)

3 (2.6)

Strabismus

0 (0.0)

2 (1.7)

Carotid ophthalmic aneurysm

0 (0.0)

1 (0.9)

Neurologic: migraine

2 (1.7)

1 (0.9)

Respiratory: asthma

5 (4.2)

2 (1.7)

None

70 (58.3)

72 (62.1)

Hematologic: thalassemia

0 (0.0)

1 (0.9)

Gastrointestinal

13 (10.8)

12 (10.3)

Other

0 (0.0)

3 (2.6)

Gastritis

1 (0.8)

2 (1.7)

Fibromyalgia

0 (0.0)

1 (0.9)

Functional abdominal pain

8 (6.7)

6 (5.2)

Chronic fatigue

0 (0.0)

1 (0.9)

Irritable bowel syndrome

1 (0.8)

1 (0.9)

Maple syrup urine disease

0 (0.0)

1 (0.9)

Recurrent abdominal pain of
childhood

0 (0.0)

2 (1.7)

Gastroesophageal reflux

2 (1.7)

1 (0.9)

1 (0.8)

0 (0.0)

Psychiatric

Functional dyspepsia

24 (20.0)

15 (12.9)

Anxiety

10 (8.3)

10 (8.6)

Depression

3 (2.5)

3 (2.6)

Posttraumatic stress disorder

5 (4.2)

0 (0.0)

Learning disability

1 (0.8)

0 (0.0)

Eating disorder

0 (0.0)

1 (0.9)

Attention deficit hyperactivity
disorder

5 (4.2)

1 (0.9)

Otolaryngologic

9 (7.5)

9 (7.8)

Recurrent otitis media

2 (1.7)

4 (3.4)

Obstructive sleep apnea

1 (0.8)

0 (0.0)

Environmental allergies

2 (1.7)

3 (2.6)

Recurrent tonsillitis

2 (1.7)

2 (1.7)

Hearing impairment

1 (0.8)

0 (0.0)

Branchial cleft cyst

1 (0.8)

0 (0.0)

2 (1.7)

3 (2.6)

Recurrent urinary tract
infections

2 (1.7)

2 (1.7)

IgA nephropathy

0 (0.0)

1 (0.9)

Urologic

Note: IgA = immunoglobulin A, IQR = interquartile range, SD = standard deviation.
*Except where noted otherwise.
†A single dose of acetaminophen or ibuprofen was administered before the emergency
department visit and at least 6 hours before the intervention. Ketorolac was
administered Intravenously in the emergency department 2.8 to 4.3 hours before the
intervention in all cases.
‡Ondansetron in all cases.
§Pantoprazole or orally administered mixture of bismuth salicylate and viscous lidocaine.
¶Some participants had more than 1 comorbidity; diagnoses were obtained by
self-report and from the medical record.

Results
Of 4818 children screened, 236 were randomly allocated to receive
hyoscine butylbromide (n = 120) or acetaminophen (n = 116)
(Figure 1). The follow-up survey was completed by 73% of participants
in both groups. Overall, the mean age was 12.4 (SD 3) years, and
153 participants (64.8%) were girls. One-third of participants in both
groups had received analgesia before enrolment (Table 1). Among the
212 children who were eligible but declined consent, the mean age
was 11.9 (SD 2.9) years, and 129 (60.8%) were girls.

Primary outcome
Four participants in the hyoscine butylbromide group and 1 partici
pant in the acetaminophen group did not complete the 80-minute
pain assessment. The mean pain scores before the intervention
were 60 mm (SD 18 mm) and 62 mm (SD 17 mm) in the hyoscine
butylbromide and acetaminophen groups, respectively. The
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Table 1 (part 1 of 2): Baseline characteristics of children
with nonspecific colicky abdominal pain randomized to
receive hyosine butylbromide or acetaminophen
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Table 2: Mean pain scores*
Mean score ± SD, mm
Hyoscine butylbromide
n = 120

Acetaminophen
n = 116

Adjusted difference
(95% CI)†

60.3 ± 17.9

62.3 ± 16.5

–

15 min

45.9 ± 22.5

45.5 ± 23.8

–

30 min

42.1 ± 22.9

39.3 ± 24.1

–

45 min

37.1 ± 24.4

36.7 ± 26.8

–

60 min

33.4 ± 26.4

33.7 ± 27.9

–

80 min

29.4 ± 26.4

30.1 ± 28.8

0.7 (–6.9 to 7.3)

Time
Before intervention
After intervention

Note: CI = confidence interval, SD = standard deviation.
*Assessed with a 100 mm visual analogue scale.
†Represents between-group difference in pain scores 80 minutes after the intervention, adjusted for preintervention pain scores.

corresponding scores at 80 minutes were 29 mm (SD 26 mm) and
30 mm (SD 29 mm), with an adjusted between-group difference of 1
(95% confidence interval –7 to 7) (Table 2). There was no significant
effect of any preintervention analgesia (p = 0.9), or acetaminophen
(p = 0.8), ibuprofen (p = 0.5) or ketorolac (p = 0.99) specifically, upon
the results of the primary analysis.

Secondary outcomes
Rescue analgesia was administered to 4 participants (3.3%) in the
hyoscine butylbromide and 1 participant (0.9%) in the acetaminophen group (p = 0.2). In all cases, ibuprofen or ketorolac was
administered after the 80-minute pain assessment. A pain score
less than 30 mm 80 minutes after the intervention was reported by
66 participants (55.0%) in the hyoscine butylbromide group and
63 participants (54.3%) in the acetaminophen group (p = 0.9).

Adverse effects
Adverse effects in the emergency department were reported by
32/116 (27.6%) and 28/115 (24.3%) participants in the hyoscine butylbromide and acetaminophen groups, respectively (p = 0.5) (Table 3).
There were no serious adverse effects or missed surgical diagnoses.

Other outcomes
Caregiver satisfaction was high with both hyoscine butylbromide
(median Likert score 5 [IQR 4 to 5]) and acetaminophen (median
score 5 [IQR 3 to 5]). The mean visual analogue scale pain scores
declined steadily after the intervention in both groups (Table 2). The
median time to 20% reduction in preintervention pain score was
22.5 (IQR 15 to 60) minutes in the hyoscine butylbromide and 30.0
(IQR 15 to 60) minutes in the acetaminophen group (Figure 2). The
median length of emergency department stay was 230.5 (IQR 189.8
to 292.3) minutes in the hyoscine butylbromide group and 236.0
(IQR 191.3 to 291.0) minutes in the acetaminophen group. Most participants in both groups were discharged from the emergency
department, and few returned to a health care provider for abdom
inal pain (Table 4). Pain after discharge was reported by 46/84
(54.8%) of participants in the hyoscine butylbromide and 41/84
(48.8%) of those in the acetaminophen group.

E1616

Table 3: Adverse effects in the emergency department and
at 72-hour follow-up
No. (%) of patients
Hyoscine
butylbromide

Acetaminophen

In emergency
department

n = 116*

n = 115*

Any adverse effect†

32 (27.6)

28 (24.3)

Nausea

10 (8.6)

12 (10.4)

Dizziness

15 (12.9)

8 (7.0)

Dry mouth

5 (4.3)

7 (6.1)

Photosensitivity

9 (7.8)

3 (2.6)

Vomiting

3 (2.6)

1 (0.9)

Constipation

1 (0.9)

3 (2.6)

Dry skin

2 (1.7)

2 (1.7)

Racing heart

2 (1.7)

2 (1.7)

Headache

1 (0.9)

2 (1.7)

Diarrhea

0 (0.0)

1 (0.9)

Sweating

0 (0.0)

1 (0.9)

Drowsiness

1 (0.9)

0 (0.0)

72-h follow-up

n = 84‡

n = 84‡

Adverse effect

12 (14.3)

12 (14.3)

Dry mouth

Any adverse effect†

3 (3.6)

4 (4.8)

Constipation

0 (0.0)

1 (1.2)

Vomiting

0 (0.0)

2 (2.4)

Dizziness

4 (4.8)

0 (0.0)

Light sensitivity

1 (1.2)

1 (1.2)

Hives

0 (0.0)

1 (1.2)

Drowsiness

4 (4.8)

2 (2.4)

Headache

2 (2.4)

2 (2.4)

p value

0.5

0.99

*Denominator reflects the number of participants who completed the 80-minute pain score.
†Some participants reported more than 1 adverse effect.
‡Denominator reflects the number of participants for whom telephone follow-up alone
was performed.
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Time from preintervention measure, min

Figure 2: Kaplan–Meier survival analysis, showing time to reduction in visual analogue scale pain score after intervention.

Table 4: Discharge diagnoses, disposition from emergency
department and follow-up
No. (%) of participants
Hyoscine
butylbromide
n = 116

Acetaminophen
n = 115

Abdominal pain not yet
determined

77 (66.4)

77 (67.0)

Gastroenteritis

37 (31.9)

27 (23.5)

Functional abdominal pain

0 (0.0)

10 (8.7)

Irritable bowel syndrome

2 (1.7)

1 (0.9)

Admitted†

3 (2.6)

2 (1.7)

Discharged

113 (97.4)

113 (98.3)

Returned to medical care for
abdominal pain

6 (5.2)

4 (3.5)

Hospital admission

1 (0.9)

0 (0.0)

46 (54.8)
(n = 84)

41 (48.8)
(n = 84)

Variable
Discharge diagnosis*

Disposition

72-h follow-up‡

Ongoing abdominal pain§

*Based largely on physician judgment.
†Admitted by the pediatric general surgery service for observation.
‡Data obtained via telephone survey; for participants who could not be reached by
telephone, data were obtained from the electronic medical record and therefore reflect
the limits of the system’s catchment area.
§Telephone survey alone.

Interpretation
In this randomized controlled trial, we found that hyoscine butylbromide was not superior to acetaminophen in children with nonspecific
abdominal pain in the highly selected patients randomized. Our findings suggest that either agent may be routinely considered for children with nonspecific colicky abdominal pain in the emergency
department. Among adults, a reduction of 30 mm or more on a visual
analogue scale corresponds to “adequate pain control,”47 and a
decrease of 30% or more from baseline has been deemed clinically
significant in irritable bowel syndrome.48 We observed a decrease
from baseline of roughly 50% in both groups, but this was achieved
by less than 60% of participants. However, caregiver satisfaction was
high in both groups. Pain severity at discharge and satisfaction with
pediatric emergency department care are poorly correlated,49,50 and
caregiver satisfaction may reflect a “personal evaluation of health
care services and providers,”51 along with the message that pain management is a priority.49,52 Ongoing pain after discharge was reported
by about half of participants in both groups, which shows the need
for appropriate discharge instructions regarding analgesia. More than
half of participants in both groups received analgesia before enrolment. The possibility of a residual analgesic effect complementing
that of the intervention was unlikely because we excluded participants who had received analgesia within 6 hours, the therapeutic
window of both hyoscine butylbromide and acetaminophen.
Our findings are in keeping with those of adult studies of orally
administered hyoscine butylbromide for colicky abdominal pain that
showed decreases in pain of 59%53 and 30%.54 In the only known
pediatric study of hyoscine butylbromide, the medication was compared to Spascupreel (Biologische Heilmittel Heel), a homeopathic
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preparation, in children with recurrent gastrointestinal or urethral
spasms; the study reported that both agents were beneficial, with few
adverse effects.30 Although hyoscine butylbromide is an antimuscarinic agent, the butylbromide moiety limits systemic absorption, and,
therefore, systemic anticholinergic effects are uncommon.28,29,46 To
our knowledge, no pediatric studies have explored acetaminophen
for nonspecific abdominal pain. Remington-Hobbs and colleagues46
found that, in adults, acetaminophen was superior to intravenously
given hyoscine butylbromide for “undifferentiated” abdominal pain.
Hyoscine butylbromide is available in Canadian emergency departments but must be ingested as an intact pill. Acetaminophen may be
a more feasible option because it is available over the counter and
inexpensive, and can be administered to children of all ages. Adopting
a therapy with a time to effective analgesia of 60–80 minutes post
intervention may be difficult in an acute care setting. In our study, the
median length of stay was more than 3.5 hours in both groups, consistent with data from a US cohort of children with “undifferentiated”
abdominal pain (3.4 h).5 We did not record the number of diagnostic
tests, but tests may have contributed to length of stay,55,56 and triagebased directives may facilitate more timely analgesia and discharge.57
Future studies should explore the effectiveness of a higher dosage of hyoscine butylbromide (20 mg), hyoscine patches or combining pharmacologic therapies with nonpharmacologic strategies
such as cognitive behaviour therapy.58 Where possible, should eth
ical approval allow, studies could include a placebo arm to test
whether an active comparator is associated with earlier symptom
resolution and whether the benefits of therapy offset the costs.

Limitations
The observed decreases in pain in our study may have been due to
the study medications, the natural history of nonspecific abdom
inal pain,59 satisfaction that diagnostic investigations were negative
or “tincture of time.” Definitively attributing analgesia to the intervention would have been possible with a placebo arm. Nevertheless, it remains likely that participants in both groups benefited
from the interventions. Following pain duration of roughly 2 hours
before enrolment, pain scores had decreased by about 50% in both
groups 60–80 minutes after the intervention, the time of peak analgesic effectiveness of both agents.19,34,35 In adult emergency department patients, intravenously administered hyoscine butylbromide
and orally administered acetaminophen were associated with
decreases greater than 50% in “undifferentiated” abdominal pain
at 60 minutes.46 In the present study, many screened patients were
excluded because of suspected underlying causes of the abdominal
pain, which may limit external generalizability. We focused on nonspecific pain because it is the most common form of abdominal
pain among children presenting to the emergency department.8,9
We limited enrolment to children with colicky pain because we
believed it was amenable to relief with hyoscine butylbromide, an
inhibitor of acetylcholine-mediated intestinal smooth muscle contraction.19 Furthermore, we limited enrolment to patients able to
verbalize symptoms consistent with colicky abdominal pain; thus,
our findings may not apply to patients with other types of abdom
inal pain. Although we were able to determine return visits for
almost all participants, for roughly a quarter, we could not determine whether they had persistent pain or delayed adverse effects.
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Conclusion
Hyoscine butylbromide was not superior to acetaminophen in
children with nonspecific colicky abdominal pain, but both were
associated with a clinically important benefit. Our results suggest
that either hyoscine butylbromide or acetaminophen can be considered for children with nonspecific colicky abdominal pain, the
latter being more practical. Definitive recommendations require a
placebo-controlled trial to determine whether the benefits of providing analgesia are clinically important compared to no analgesia
with respect to outcomes such as emergency department length
of stay, satisfaction and side effects.
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